• By ICR Secretariat
  • Posted Monday, August 5, 2019

Amgen's KRAS drug shows promise in 2 additional cancers: colorectal and appendiceal


Amgen’s KRAS inhibitor made a splash at this year’s American Society of Clinical Oncology (ASCO) annual meeting, and with good reason—it was the first drug of its class to post clinical data.